facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
6/2021
vol. 108
 
Share:
Share:
abstract:
Review article

Herpes zoster vaccination. An update

Khairuddin Djawad
1
,
Safruddin Amin
1
,
Anni Adriani
1
,
Widyawati Djamaluddin
1
,
Dirmawati Kadir
1
,
Sri Vitayani Muchtar
1

1.
Department of Dermatology and Venereology, Faculty of Medicine, Hasanuddin University, Makasar, Indonesia Klinika Dermatologii i Wenerologii, Wydział Medycyny, Uniwersytet Hasanuddin, Makasar, Indonezja
Dermatol Rev/Przegl Dermatol 2021, 108, 517-525
Online publish date: 2022/03/23
View full text Get citation
 
PlumX metrics:
Herpes zoster/shingles is a cutaneous condition caused by the reactivation of varicella zoster virus. The condition mostly occurs when the cell mediated immunity towards varicella zoster virus, which was developed during the varicella zoster virus primary infection that causes varicella, decreases with increased age. The disease can cause various complications, most notably post herpetic neuralgia, which cause both significant health and socioeconomic burden, as well as impact the patient’s quality of life. One of the steps we can take in combating this matter is vaccination. This article seeks to review the current options of herpes zoster vaccination and its efficacy, from the long-established live attenuated zoster vaccine and the recombinant adjuvant subunit vaccine.
keywords:

herpes zoster, live attenuated zoster vaccine, recombinant adjuvant subunit vaccine



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.